WIB-San Francisco Bay Area: Clinical Trials in the Digital Age – AI and Digital Health Technologies

On February 27, 2025, WIB-San Francisco Bay Area convened a panel of experts to explore the evolving landscape of clinical trials in the digital age. The event featured Dr. Hala Borno of Trial Library, Dr. Angela Jimenez of Leon Precision Capital, Mui Van Zandt from IQVIA, Michelle Yi from Women In Data, and Dr. Nichole Young-Lin of Google and was attended by 63 participants. Moderated by Tais Richardson of the Passarini Group US, the panel addressed the practical applications and challenges of integrating AI/ML technologies and digital health innovations into clinical research and patient care.

The discussion highlighted specific use cases for AI in clinical trials, including improved patient identification and recruitment, streamlined study design, and enhanced patient engagement. Panelists emphasized the potential for machine learning to formulate hypotheses during drug development, improve diagnostics, and leverage real-world data to refine trial expectations and track outcomes. They also underscored the importance of a 'safety first' approach, acknowledging the potential for unintended consequences, such as data bias, and advocating for responsible implementation. Creative applications of AI/ML technologies were explored, particularly in conjunction with digital tools like wearables and personalized health apps. The panel discussed how these innovations can contribute to making healthcare more accessible, inclusive, and beneficial. The panel highlighted the excitement surrounding technology's ability to personalize treatment strategies. This led to a discussion on the importance of ensuring that these technologies are used in a way that minimizes risk and maximizes patient benefit.

Following the panel discussion, attendees actively participated in a lively Q&A session, posing thoughtful questions, and engaging in further dialogue. This interactive exchange highlighted the audience's keen interest in the practical implications and future directions of AI and digital health in clinical trials. The event concluded with a networking session, allowing participants to connect and continue the conversation over hors d'oeuvres. The event successfully provided a comprehensive overview of the current state and future potential of AI and digital health technologies in clinical trials. The event successfully provided a comprehensive overview of the current state and future potential of AI and digital health technologies in clinical trials, underscoring the need for continued innovation, collaboration, and ethical implementation to ensure these advancements translate into faster, more efficient, and more inclusive patient outcomes.

A heartfelt thank you to the sponsor IQVIA and the host Capgemini for providing an evening for professionals to discuss how digital technologies can accelerate clinical trials.

Submitted by Veronica Garcia